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Abstract
The contribution of common genetic variation to one or more established smoking behaviors was investigated in a joint
analysis of two genome wide association studies (GWAS) performed as part of the Cancer Genetic Markers of Susceptibility
(CGEMS) project in 2,329 men from the Prostate, Lung, Colon and Ovarian (PLCO) Trial, and 2,282 women from the Nurses’
Health Study (NHS). We analyzed seven measures of smoking behavior, four continuous (cigarettes per day [CPD], age at
initiation of smoking, duration of smoking, and pack years), and three binary (ever versus never smoking, #10 versus .10
cigarettes per day [CPDBI], and current versus former smoking). Association testing for each single nucleotide
polymorphism (SNP) was conducted by study and adjusted for age, cohabitation/marital status, education, site, and
principal components of population substructure. None of the SNPs achieved genome-wide significance (p,10
27) in any
combined analysis pooling evidence for association across the two studies; we observed between two and seven SNPs with
p,10
25 for each of the seven measures. In the chr15q25.1 region spanning the nicotinic receptors CHRNA3 and CHRNA5,w e
identified multiple SNPs associated with CPD (p,10
23), including rs1051730, which has been associated with nicotine
dependence, smoking intensity and lung cancer risk. In parallel, we selected 11,199 SNPs drawn from 359 a priori candidate
genes and performed individual-gene and gene-group analyses. After adjusting for multiple tests conducted within each
gene, we identified between two and five genes associated with each measure of smoking behavior. Besides CHRNA3 and
CHRNA5, MAOA was associated with CPDBI (gene-level p,5.4610
25), our analysis provides independent replication of the
association between the chr15q25.1 region and smoking intensity and data for multiple other loci associated with smoking
behavior that merit further follow-up.
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Introduction
Cigarette smoking is a risk factor for more than two dozen
diseases and the single biggest cause of preventable mortality
worldwide [1]. Although public awareness of the dangers of
smoking is widespread and public health measures such as public
building smoking restrictions and increased cigarette taxes have
had salutary effects on smoking rates, dependence on nicotine, the
major psychoactive component in tobacco, induces most people
who start smoking to continue to smoke in spite of their wish to
quit [2]. Environmental influences on tobacco dependence
including cultural perceptions and economics, low socioeconomic
status, peer smoking and maternal smoking during pregnancy are
well documented. Nevertheless, twin studies provide strong
evidence that a range of diverse smoking phenotypes including
age at initiation, intensity, and cessation have a substantial
hereditary component [1,3,4,5,6]. Identifying the specific loci that
influence smoking behaviors (including initiation, intensity and
cessation) could lead to important etiological insights and facilitate
the development of treatments to further reduce smoking related
mortality.
Genome-wide linkage studies have identified chromosomal
regions that may harbor loci contributing to one of many smoking
behavior phenotypes: age at initiation [7,8]; some variant of CPD
[9,10,11,12,13,14,15,16,17] DSM-IV Nicotine Dependence
[11,17]; some variant of Ever-Never [9,17,18,19,20]; Fagerstrom
test for nicotine dependence (FTQ, FTND) or Heaviness Smoking
Index (HIS) [14,21,22]; Pack-years [9,23]; Current versus Former
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4653[11]; and withdrawal severity [11]. While some regions have
shown suggestive linkage to smoking behaviors in multiple studies
[24], linkage results have generally been heterogeneous and short
on conclusive findings; to date no risk loci have been discovered
that definitively account for linkage signals.
Until very recently, candidate gene association studies have
focused on genes in a few candidate pathways. A ‘reward deficiency
syndrome’ has been postulated as one unifying theme to account for
the role of diverse neurotransmitters in nicotine dependency
[25,26,27], and consequently many studies have evaluated genes in
opioid [28,29], serotinergic [30,31,32], dopaminergic [26,33,34,35],
drug metabolizing enzyme [36,37,38,39,40,41] and nicotinic and
muscarinic cholinergic receptor pathways[42,43]. Results from these
studies have been largely equivocal, due to small sample sizes in
individual studies, incomplete and non-overlapping genetic coverage,
differences in measures of smoking behavior, or differences in genetic
and environmental backgrounds. It is also highly probable that many
of the loci that influence smoking behavior lie outside of the
previously-studied candidate regions.
A recent genome-wide association study of over 13,000 smokers
identified a region on chromosome 15q25.1 associated with
smoking intensity (number of cigarettes smoked per day) [44]. This
region, spanning the nicotinic acetylcholine receptors, CHRNA5,
and CHRNA3, and CHRNB4 and was also identified in a recent
GWAS of dichotomized smoking intensity [45], and in two
genome-wide association scans of lung cancer [46,47], It was
unclear whether the association between SNPs in this region and
lung cancer was due to a genetic effect on smoking behavior, an
independent effect on lung carcinogenesis, or both [48]. Two
recent candidate gene studies together including almost 5000
smokers both found SNPs in nicotinic receptors including the
chr15p25.1 nicotinic receptor loci to be associated with nicotine
dependence [49,50].
To identify loci associated with smoking initiation, intensity and
cessation we performed a genome-wide association study (GWAS)
using data from subjects genotyped as part of the Cancer Genetic
Markers of Susceptibility (CGEMS) project, including 2,617 ever-
smokers [51,52]. In addition to single-marker tests of association
in the GWAS, we also report results from gene- and gene-group-
level tests of association of 359 candidate genes in 30 functional
groups.
Methods
Samples and genotypes
Subjects were drawn from two previous genome-wide associa-
tion studies (GWAS), performed as part of the Cancer Genetic
Markers of Susceptibility (CGEMS) project [51,52]. Data on
smoking behaviors were available on 2,060 men from the Prostate,
Lung, Colon and Ovarian Trial (PLCO) (1,172 prostate cancer
cases and 1,157 controls) and on 2,282 postmenopausal women
(1,145 with breast cancer and 1,142 controls) from the Nurses’
Health Study (NHS). All subjects were of self-reported European
ancestry, which was consistent with genetic analyses of population
structure [53]. Samples from the PLCO were genotyped using the
Illumina HumanHap 300 k and HumanHap 240 k platforms
[52]; those from the NHS were genotyped using the Illumina
HumanHap 550 k platform [51]. Genotyping was performed at
the same laboratory and similar genotyping quality control (QC)
procedures were used in each study. Individual samples were
removed if more than 10% of SNPs failed genotyping, and
individual SNPs were removed if more than 10% of samples failed.
The average call rate for both PLCO and NHS samples was
99.8%. Combined genome-wide analyses were restricted to
directly-genotyped SNPs with minor allele frequencies above 1%
in each study (ca. 518,000 SNPs). Additional description of these
studies is available in previous reports [51,52].
Adjustment for population stratification
For both PLCO and NHS, analyses of population stratification
were conducted using approximately 10,000 unlinked SNP
markers [51,52]. Individual European, Asian and African
admixture proportions were estimated by STRUCTURE [53]
applied to CGEMS data augmented by the HapMap CEU,
CHB+JPT and YRI samples. Subjects with significant non-
European admixture were excluded for PLCO and NHS.
Residual within-Europe population stratification was estimated
using the top three (PLCO) or four (NHS) principal components of
genetic variation, as calculated using EIGENSTRAT [54].
Smoking behaviors
We selected four continuous and three binary smoking
behaviors for analysis (Table 1). The continuous measures were
cigarettes smoked per day (CPD), age at smoking initiation
(SMKAGE), duration of smoking (SMKDU) and pack-years
(PKYRS); the binary measures were ever versus never smoking
Table 1. The distribution of smoking behaviors and
covariates in NHS and PLCO CGEMS samples.
Smoking Behaviors or Covariates *
NHS
(n=2282)
PLCO
(n=2060)
CPD (Cigarettes per day, mean6SD) 18.5610.5 22.0613.6
SMKAGE (Age of initiation, years, mean6SD) 19.663.7 18.165.0
SMKDU (Duration, years, mean6SD) 25.3615.5 27.7613.8
PKYRS (Pack-years, mean6SD) 24.9622.2 31.8627.3
EVNV (N, %)
Ever smokers 1244 (55) 1373 (67)
Never smokers 1038 (45) 687 (33)
CIGSTAT (N, %)
Former smokers 1107 (89) 1161 (85)
Current smokers 137 (11) 212 (15)
CPDBI (N, %)
.10 CPD 906 (75) 1167 (85)
#10 CPD 305 (25) 202 (15)
Living Status (N, %)
Alone/not married 457 (20) 271 (13)
Not alone/married 1825 (80) 1789 (87)
Education (N, %)
No college 0 838 (41)
Some college 1591 (70) 409 (20)
Bachelors 463 (20) 392 (19)
Masters or above 228 (10) 421 (20)
Age (N, %)
55–59 years 111 (5) 400 (19)
60–64 437 (19) 648 (31)
65–69 411 (18) 651 (32)
70–74 581 (26) 361 (18)
.74 742 (32) 0
*descriptive statistics for smoking behaviors included ever smokers only.
doi:10.1371/journal.pone.0004653.t001
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(CIGSTAT), and a binary measure of smoking intensity (CPDBI,
defined as ten or more cigarettes per day versus fewer than ten).
Only current or former smokers were included in the analyses
involving the smoking phenotypes with the exception of EVNV
which included never smokers.
All of these behaviors were measured by baseline questionnaire
(BQ) in the PLCO (administered from 1994–2001) [55]. Age at
initiation was defined as the age when a subject started smoking
‘‘regularly for six months or longer.’’ Former smokers were defined
as ever-smokers who did not smoke regularly at BQ and were
asked to report the age at which they stopped smoking regularly.
Ever smokers were asked to provide information on the number of
cigarettes they smoked per day, in categories (1–10, 11–20, 21–30,
31–40, 41–60, 61–80, over 80). For continuous analyses we
assigned subjects to the midpoint of their category (or 90 cigarettes
per day for over 80). Duration was derived from data on age at
smoking initiation and age at cessation. Pack years was derived by
converting cigarettes per day to packs per day (CPD/20) and
multiplying this figure by duration.
In the NHS, SMKAGE was measured at BQ; all other
behaviors were measured using cumulative information from the
BQ (administered in 1976) and subsequent follow-up question-
naires (one every two years). The majority of NHS subjects (2149)
had smoking data available up through the 2002 questionnaire.
For those few women (133) with no smoking data available from
the 2002 follow-up cycle, we used data from the latest available
follow-up. Age at initiation was defined as the age when a subject
started smoking cigarettes ‘‘regularly.’’ Former smokers were
defined as ever-smokers who identified themselves as non-smokers
on any questionnaire (and did not identify as a smoker on any
subsequent questionnaire). Age at cessation was explicitly asked in
NHS BQ. For women who quit smoking after the BQ, age at
cessation was inferred as the median age between the question-
naire that defined the woman as a former smoker and the last
questionnaire that identified her as a smoker. Prior to 1982,
current or former smokers were asked to write in the average
number of cigarettes they smoked per day; subsequent question-
naires captured information about smoking intensity in categories
(1–4, 5–14, 15–24, 25–34, 35–44, and over 44 cigarettes per day).
Pack years was estimated as the sum of the products of smoking
intensity (categories were assigned midpoint values, e.g. 5–14 was
coded as 10 cigarettes per day, or 0.5 packs per day) at
questionnaire k times the interval between questionnaire k and
questionnaire k+1 (or half that interval for women who were
smokers at questionnaire k and non-smokers at questionnaire k+1).
Smoking duration was calculated as the sum of all intervals where
a woman was a smoker. Average cigarettes per day (the CPD
variable used in this GWAS) was calculated as pack-years divided
by smoking duration.
Association analyses
Continuous phenotypes were log transformed to achieve
approximate normality and SNP genotypes were coded as counts
of minor alleles. For each study, we defined any phenotype that
was more than three standard deviations from the mean to be an
outlier. Outliers that were above (below) the mean were then
truncated to the 99th (1st) percentile of the raw distribution. We
tested for association between each SNP marker and each
continuous phenotype using linear regression, adjusted for study
center (PLCO) or geographic region (NHS); age at smoking
assessment in five-year bins (baseline for PLCO or last available
follow-up for NHS); marital status (married versus not; PLCO) or
living arrangement (living alone or with others, NHS); education
(4 categories PLCO, 3 categories NHS); prostate (PLCO) or breast
(NHS) cancer case-control status; and selected principal compo-
nents of genetic variation. For binary traits, we used unconditional
logistic regression, adjusted for the same covariates. These tests
were conducted separately for PLCO and NHS. For SNPs that
passed QC filters and had minor allele frequency above 1% in
both studies, we combined evidence for association across PLCO
and NHS using weighted Z-scores [56]. Heterogeneity in SNP-
smoking behavior associations across study was assessed using Q
and I
2 statistics [57]. Power calculations were performed using
Quanto (http://hydra.usc.edu/GxE/)[58]
Analyses of candidate genes and candidate gene groups
We selected 359 genes for additional analyses, based on their
hypothesized relationship to smoking behavior. 349 of these genes
were previously selected by the NICSNP Candidate Gene
Committee [50]. We added ten candidate genes identified from
two recent GWAS of dichotomized measures of nicotine
dependence (CTNNA3, FBXL17, FTO, NRX1, PBX2, TRPC7,
VPS13A) and CPD (DGK1, RORB, SLCO3A1) [45,59].
For each candidate gene we tested the null hypothesis that no
SNP within 20 kb upstream of the start of transcription and 10 kb
downstream of the stop of transcription (based on NCBI build
35.1) was associated with smoking behaviors using a parametric
permutation procedure that allows for covariate adjustment. We
compared the smallest observed p-value for any SNP in the
candidate gene region to the empirical null distribution of the
smallest p-value based on 20,000 random permutations. This
approach provides a gene-level p-value that is adjusted for both
the number of SNPs in the gene region and their linkage
disequilibrium structure.
Candidate genes (and the SNPs in the corresponding gene
regions) were grouped based on known functional similarity. We
used a slightly modified version of the groups developed by the
NICSNP Candidate Gene Committee. (Table S1). To test for
association between SNPs in a group and smoking behaviors, we
used a modified rank truncated product method [60] which
compares the product of the ten smallest gene-level p-values over
all the genes in the group to its simulated null distribution. Such a
group or pathway level analysis potentially has more power to
detect associations when a group containing multiple susceptibility
genes each has modest evidence for association [61].
Chr15q25.1 SNP imputation
Multiple SNPs in the 15q25.1 region have been shown to be
associated with CPD, nicotine dependence, or risk of lung cancer
[44,47,49,50,59]. We directly genotyped some of these SNPs and
could impute others using the observed genotypes in PLCO and
NHS samples and the phased HapMap CEU samples (Release
21). Imputation, restricted to the region of chromosome 15q23,
was performed for each study separately using the Hidden Markov
Model implemented in Mach 1.0 [62]. All of the imputed
genotypes had high quality scores (R-squares.0.8 for 95% of
SNPs in the region).
Results
The distributions of the smoking behaviors and demographic
covariates included in the analysis of the NHS and PLCO datasets
are presented in Table 1. The men in the PLCO sample have
smoking behaviors that are more prevalent and more severe
(greater frequency of ever, current and heavy smokers, earlier age
of onset, longer duration, and greater pack-years) than do the
women in the NHS sample. The direction and significance of
GWAS of Smoking Behaviors
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similar, with all correlations highly significant (P,0.0001), except
for the correlation between age at initiation and cigarettes per day
in the NHS sample (Table S2).
Quantile-quantile plots of the 2log10 p-values for SNP
association with smoking behaviors (Figure S1) showed no
evidence for systematic bias (each genomic inflation factor
l,1.02). None of the SNPs achieved genome-wide significance
(p,10
27) in any combined analysis pooling evidence for
association across the two studies (Figures 1 and 2). Table 2 lists
detailed results for SNPs with a combined-analysis p-value,10
25
for each smoking behavior. For the combined GWAS analysis of
the seven smoking behaviors, the most significant SNP smoking
behavior association result is rs6437740 with CPD (P=2.4610
27).
Including this result, there are 8 gene regions and 3 genomic
regions with predicted but not verified coding regions associated
with SNPs in the group of SNP smoking behavior results with
P,10
25 (Table 2). We observed no evidence for systematic
heterogeneity in results between studies, and no single SNP
showed evidence for heterogeneity by sex at the genome-wide
significance level (see summary of Q statistics in Figure S2).
We analyzed 359 candidate genes previously nominated as
candidate genes for nicotine dependence [50], or identified in
GWAS studies of dichotomized nicotine dependence and CPD
[45,59] and gene-level results are summarized in Table 3. Of note,
rs3027409 in the MAOA candidate gene region had a p-value of
6.7610
26 for association with CPDBI, which led to a gene-level p-
value smaller than 5.4610
25, the smallest a priori candidate gene
association we observed. Nine candidate gene groups were
associated with at least one smoking behavior at the 0.10 level
(Table 4) with two (Nicotinic Receptors and Voltage-Dependent
Calcium-Activated Potassium Channels) associated with a smoking
behavior (CPD) at the 0.01 level.
Figure 3 and Table S3 summarize the associations between
genotyped and imputed SNPs and CPD in PLCO and NHS
smokers for the chr15q25.1 region spanning CHRNA3 and
CHRNA5. The strongest association signal we observe in this
region is at rs2036527 (combined P=8610
25), located 10,051
base pairs 39 of PSMA4 and 6,290 base pairs 59 of CHRNA5 in a
region of strong linkage diseqilibrium spanning both genes.
Discussion
We performed genome wide association analyses for seven
related smoking behaviors in two datasets totaling 4,611
individuals and 2617 ever smokers. We selected smoking behaviors
with established hereditary components [4,5,21,63] and public
health relevance[64,65]. To the best of our knowledge this study
represents the first genome-wide association study of duration of
smoking, pack years, and age at initiation of smoking. The sample
size is also larger than most published candidate gene association
studies of smoking behavior [66] and two previous genome-wide
association studies of smoking behaviors [45,59].
Although we did not discover novel genome-wide significant
(p,10
27) associations, we did find additional evidence for an
association between genetic variants in the chr15q25.1 region and
number of cigarettes smoked per day. Candidate gene analyses also
provided suggestive evidence for association between variants in the
MAOA gene region and the smoking behavior cigarettes per day.
The lack of genome-wide significant results suggests that
common variants have at most a modest influence on smoking
behavior. We had adequate power to detect a variant that
Figure 1. 2log10 p-values for association with seven continuous (Figure 1) and categorical (Figure 2) smoking behaviors. P-values are
based on the combined evidence for association from both PLCO and NHS.
doi:10.1371/journal.pone.0004653.g001
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61% power in the NHS sample and 71% power in the PLCO
sample to detect such a variant at the 10
27 level; the power of the
combined analysis was greater than 99%. Conversely, the lack of
genome-wide significant findings does not rule out the existence of
(many) common variants with small individual effects on smoking
behavior, since our power to detect any one is small. Even with
our relatively large sample size, our power to detect a variant
similar to the 15q25.1 SNP rs1051730 (which was estimated to
explain about 0.7% of the trait variance [44] at the genome-wide
significance level) was only 8.5% for the combined analysis (and
less than 1% for either study alone).
SNPs at the nicotinic receptor candidate genes CHRNA3
(chr15q25.1) and CHRNA1 (chr2q31.1) are associated in the
CGEMS sample with three smoking behaviors: CPD, PKYRS and
SMKAGE (Table 3). Another candidate gene association study
investigating 348 of 359 candidate genes included in this study
[50] evaluated association with a dichotomized nicotine depen-
dence phenotype, and identified nicotinic receptor SNPs associ-
ated with FTND, including rs578776 and rs1051730 within
CHRNA3, and rs16969968 within CHRNA5. Nicotinic receptors
are also associated with CPD in the candidate gene group analysis
as the most significantly associated gene group, and also with the
phenotype SMKDU (Table 4).
Finally, we combined our chr15q25.1 results with data from
three other published reports (Table S3) [44,46,47]. The SNP
rs1051730, found within CHRNA3 (Ex5+268), was highly
statistically significantly associated with CPD (p=5610
232); the
SNP rs8034191 (LOC123688 IVS2+256) was also highly statisti-
cally significantly associated with CPD (p=2610
229). These SNPs
were evaluated using a total of 26,789 (rs1051730) or 24,891
(rs8034191) smokers from this study and two other reports. The
CHRNA5 SNP rs16969968 (Ex5-54, D398N) was significantly
associated (p,.01) with CPD in this study but not an earlier,
smaller study; combined evidence for association in 3,464 smokers
remained significant (p=2610
23). Comparative judgments of the
relative importance of the individual SNPs are not possible due to
the different sample sizes, the strong LD among the SNPs and the
inability to adjust for the effects of the other SNPs in this meta-
analysis.
Our candidate gene analyses identified an association
(rs3027409, p,5.4610
25) between genetic variation in MAOA
and a dichotomized measure of smoking intensity (10 or less
cigarettes smoked per day versus more than 10). This was the only
gene-level result that remained significant after Bonferroni
correction for the number of genes tested, which we regard as a
conservative multiple-testing correction. This association is notable
because of the role of the monoamine oxidases in the regulation of
catecholamines and the inhibition of monoamine oxidases A and B
by tobacco smoke [67]. There is substantial evidence that smoking
results in reduced levels of the monoamine oxidase enzymes
[67,68] and subsequent reduced catabolism of dopamine likely
contributes to the reinforcing and motivating effects of smoking.
Investigation of MAO-related polymorphisms in relation to
alcoholism [69,70], Parkinson disease [71,72,73] and smoking
[34,67,70,74,75,76,77] have yielded mixed results; our results
suggest further investigation of this X-chromosome locus is
warranted.
The gene group analysis that we performed provides one way to
summarize the statistical evidence for association between a trait
and multiple genetic variants across groups of genes that share
sequence similarity and function. Nicotinic cholinergic receptors
Figure 2. 2log10 p-values for association with seven continuous (Figure 1) and categorical (Figure 2) smoking behaviors. P-values are
based on the combined evidence for association from both PLCO and NHS.
doi:10.1371/journal.pone.0004653.g002
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significantly associated with CPD (gene group P,0.01). We have
previously discussed nicotinic receptor findings above. The
association of rs7050529 (IVS3+286 of TRPC5) with CPD
(Table 2) is notable as a closely related family member, TRPC7,
was previously significantly associated with nicotine dependence
[59]. The transient receptor potential cation family is a
superfamily of 28 genes coding for cationic ion channels
responding to temperature, endogenous and exogenous organic
compounds, Ca2+ flux, and mechanical stimuli, and are expressed
in nearly every tissue [78]. This study, the NICSNP study and
Feng et al., 2006 [79] have identified significant associations
between five Transient Receptor Family Potential (TRP) subfam-
ily members and nicotine related behaviors in the canonical (this
study Table 2, [59] Table 1, and [79]) and vanilloid subfamilies
(this study Table 3, and Saccone et al., 2007, Supplementary
Material [50]). Recently, Gu et al., 2005 [80] have shown that
vanilloid subfamily members are expressed in the lung and are
responsible for the pulmonary chemoreflex response, suggesting
further study of these TRP subfamilies and their potential role in
smoking behavior and downstream consequences may be fruitful.
The cytochrome P450, cell cycle control, and alcohol
dehydrogenase candidate genes groups also exhibited nominally
significant (0.01,Ppermuted,0.05) associations with smoking be-
haviors (Table 4). The cytochrome P450 results may have been
driven by association between SNPs at CYP2B6 with EVNV, and
CYP2A6 and SMKAGE (Table 3). These results are consistent
with evidence for the relationship between CYP2A6 genetic
variation and both nicotine metabolism [81,82,83] and smoking
behavior [41,84].
In our study, the observed association between cell cycle control
genes and quit status may be driven by association of SNPs at
FBXL17 (gene-level, p=0.021, rs1433050) and NFKB1
(rs10489113, gene-level P=0.022). FBXL17 is one of 68 members
of the human F-box protein superfamily, a large group of ubiquitin
ligases [85]. Ubiquitin ligases function in the ubiquitin-proteasome
complex, which regulates protein assembly, trafficking and
degradation, a cellular activity itself regulated by nicotine [86].
Table 2. SNPs with Pweight,10
25 for seven smoking behaviors in 4,611 men and women of European ancestry.
Smoking Behavior SNP Chr Coordinate Gene Region
maf
NHS
maf
PLCO
beta
NHS
beta
PLCO P NHS P PLCO P weight Q
CPD rs6437740 3 108,948,507 BBX 0.23 0.24 20.14 20.10 3.70E-05 1.30E-03 2.40E-07 0.90
rs910696 1 30,236,689 0.30 0.31 0.11 0.08 2.20E-04 3.30E-03 3.00E-06 0.64
rs10411195 19 19,897,176 ZNF505 0.02 0.03 20.37 20.21 2.80E-04 5.10E-03 5.80E-06 1.52
rs7050529 X 110,961,378 TRPC5 0.06 0.07 20.28 20.06 2.80E-06 7.30E-02 6.20E-06 9.75
rs758642 17 3,733,656 CAMKK1 0.35 0.34 0.10 0.08 7.00E-04 3.00E-03 7.30E-06 0.21
SMKAGE rs11082304 18 18,974,971 CABLES1 0.49 0.49 0.02 0.03 2.70E-03 6.80E-04 6.00E-06 0.70
rs17050782 4 140,780,739 SET7 0.21 0.21 0.02 0.03 4.50E-03 5.60E-04 8.40E-06 1.17
SMKDU rs7553864 1 87,325,379 AK002179 0.41 0.39 0.12 0.08 9.80E-04 8.40E-04 2.70E-06 0.52
rs719015 1 87,323,731 AK002179 0.42 0.40 0.13 0.07 2.70E-04 3.60E-03 3.80E-06 1.56
rs912969 13 102,665,105 0.07 0.07 20.24 20.14 8.50E-04 2.70E-03 7.80E-06 1.19
rs950063 4 126,789,524 0.38 0.39 20.12 20.08 1.50E-03 1.90E-03 9.00E-06 0.68
PKYRS rs800082 3 145,822,903 0.44 0.42 0.16 0.12 1.00E-03 1.00E-03 3.30E-06 0.48
rs9289678 3 145,789,794 0.43 0.42 0.16 0.12 1.20E-03 9.60E-04 3.70E-06 0.42
EVNV rs1402279 12 76,231,853 0.05 0.05 20.52 20.41 1.80E-04 7.30E-03 5.20E-06 0.27
rs933688 5 90,798,504 LOC133789 0.15 0.17 0.20 0.39 1.60E-02 5.10E-05 5.70E-06 2.14
rs1889899 9 26,779,940 0.39 0.37 0.20 0.23 1.60E-03 1.10E-03 5.70E-06 0.16
rs6452953 5 90,758,790 0.16 0.17 0.20 0.39 1.80E-02 5.60E-05 7.00E-06 2.18
rs6862125 5 90,760,354 0.15 0.17 0.20 0.39 2.00E-02 5.90E-05 8.50E-06 2.23
rs6444087 3 187,104,531 0.26 0.26 0.22 0.25 1.40E-03 2.10E-03 9.20E-06 0.05
rs1400363 4 104,608,326 0.42 0.42 20.15 20.26 1.30E-02 1.40E-04 9.90E-06 1.59
CIGSTAT rs10989661 9 101,702,423 0.25 0.26 20.30 20.52 4.50E-02 1.50E-05 6.30E-06 1.37
rs1847461 12 89,579,976 0.06 0.06 20.84 20.59 4.50E-04 4.90E-03 8.20E-06 0.64
rs10859032 12 89,599,693 0.06 0.06 20.84 20.58 4.40E-04 5.10E-03 8.40E-06 0.67
CPDBI rs3112740 16 7,776,298 0.14 0.14 0.38 0.77 1.00E-02 1.50E-04 6.00E-06 2.38
rs2268983 14 68,478,450 ACTN1 0.48 0.49 20.24 20.42 1.10E-02 1.60E-04 6.70E-06 1.43
rs3027409 X 43,363,287 MAOA 0.05 0.05 20.50 20.55 1.40E-02 1.10E-04 6.70E-06 0.04
rs886716 7 26,330,858 0.32 0.31 20.26 20.42 9.60E-03 2.10E-04 7.70E-06 1.13
rs4722613 7 26,385,573 LOC441205 0.13 0.14 20.38 20.50 5.00E-03 5.70E-04 9.30E-06 0.38
Maf=minor allele frequency.
Beta=per-minor-allele change in the mean trait value for continuous traits, and the per-minor-allele change in odds for binary traits.
p-weight=the meta-analysis p-value for the combined NHS and PLCO, using Stouffer’s method.
Q=test for heterogeneity in genetic effect between studies.
doi:10.1371/journal.pone.0004653.t002
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significantly associated with FNTD, via another SNP
(rs10793832). None of the SNPs in the same high linkage-
disequilibrium bin as rs10793832 (according to the Pelegen
genome browser) were in high linkage disequilibrium with
rs1433050, the FBXL17 SNP identified in this study. One SNP
genotyped in this study (rs885624) was in the same LD block as
rs10793832 but was not significantly associated with quit status in
either this study alone or in the combined analysis (p=0.39).
The finding that the alcohol dehydrogenases genes were
significantly associated with the smoking behavior EVNV in this
analysis (e.g., ADH4 gene-level P=0.048 (rs3828541), and ADH6,
gene-level P=0.034 (rs3857224) suggests that genetic variation at
these ADH loci may influence the establishment of smoking
behavior. However this analysis did not control for alcohol
consumption and so this finding should be considered preliminary.
Because of the large number of male and female smokers, we
were able to conduct genome-wide association scans stratified by
gender (study), and conduct a genome-wide association scan for
differences in genetic effect between men and women. Such
analyses are important, because the effect for some loci may differ
between men and women or be restricted to one gender, e.g., due
to differences in the environment. However, no SNPs achieved
genome-wide significance for association with any smoking
behavior in either study, and no SNP achieved genome-wide
significance for heterogeneity in effect between men and women
(between studies).
This study has several strengths. We performed a GWAS and
candidate gene study investigating a variety of smoking behaviors
Table 3. Candidate gene results with gene-level P,0.01 for seven smoking behaviors.
Smoking
Behavior
Candidate Gene
Region
1 N SNPs Significant SNP GWAS Pweight Permuted P beta PLCO beta NHS
CPD MAOA 8 rs2235186 3.87E-04 1.90E-03 0.03 0.11
TRPV1 28 rs4790520 9.52E-05 2.43E-03 0.07 0.10
CHRNA3 15 rs12914385 3.20E-04 3.05E-03 0.05 0.09
CHRNA5 8 rs1051730 6.13E-04 3.10E-03 0.04 0.09
FOSB 5 rs2238686 1.63E-03 6.86E-03 20.09 20.09
SMKAGE SLC1A2 55 rs16927393 2.89E-05 1.10E-03 0.05 0.05
CYP2A6 2 rs8102683 1.57E-03 2.76E-03 20.03 20.01
RYR1 33 rs8107027 2.32E-04 7.14E-03 0.01 0.08
CHRNA1 8 rs2646165 1.45E-03 9.29E-03 0.01 0.04
SMKDU GRM1 49 rs12197749 9.81E-05 3.24E-03 0.07 0.15
NCOA1 11 rs9309308 3.74E-04 3.48E-03 0.06 0.13
ADCY3 27 rs2278483 4.46E-04 7.29E-03 0.06 0.12
PKYRS MAOA 8 rs2235186 6.09E-05 1.90E-04 0.06 0.18
GRM6 12 rs1845940 3.68E-05 3.33E-04 0.13 0.14
PIK3C2G 84 rs2305220 8.04E-05 5.14E-03 0.10 0.15
GPR51 158 rs1000440 4.67E-05 5.33E-03 0.07 0.19
CHRNA3 15 rs12914385 1.04E-03 9.29E-03 0.09 0.11
EVNV CYP2B6 13 rs2014141 7.31E-05 7.36E-04 0.11 0.25
SLC6A3 23 rs464049 2.61E-04 5.79E-03 0.13 0.20
CIGSTAT GRPR 2 rs12845178 1.20E-03 1.24E-03 0.12 0.48
NR3C2 82 rs10050229 1.47E-04 8.69E-03 20.32 20.40
CPDBI MAOA 8 rs3027409 6.73E-06 5.36E-05* 20.55 20.50
ATM 9 rs609261 7.16E-04 4.81E-03 0.15 0.34
FOSB 5 rs2238686 2.22E-03 8.29E-03 20.42 20.20
*Bonferroni P value, as 20,000 permutations were too few to accurately determine the p-value in that range.
1Gene regions can overlap, so some SNPs may be in multiple gene regions.
doi:10.1371/journal.pone.0004653.t003
Table 4. Candidate Gene Groups with gene-level P,0.10.
Phenotype Candidate gene group N Genes P value
CPD Nicotinic Receptors 16 0.005
CPD Voltage-Dependent Calcium-Activated
Potassium Channels
7 0.008
SMKAGE Cytochrome P450s 5 0.032
SMKAGE Neuropeptides 10 0.062
SMKDU Cytochrome P450s 5 0.049
SMKDU Nicotinic Receptors 16 0.061
SMKDU Opioid and Opioid-Like Neuropeptides 8 0.072
EVNV Cytochrome P450s 5 0.027
EVNV Alcohol Dehydrogenases 7 0.045
CIGSTAT Cell Cycle Control 6 0.039
CPDBI Muscarinic Receptors 3 0.062
CPDBI Dopamine 12 0.074
doi:10.1371/journal.pone.0004653.t004
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unselected for smoking behaviors and/or smoking attributable
disease. We confirm important findings from recent GWAS and
candidate gene studies of nicotine dependence and CPD. Our
sample size is relatively large, yet still not large enough to reliably
detect variants with modest effects on smoking behaviors. The
absence of selection bias in the cohort bases for the samples
enhances generalizability to U.S. non-Hispanic whites although a
modest limitation is that the education level in both cohorts is
above average. By limiting analyses to subjects of European
ancestry and adjusting for principal components of population
structure, we minimized risk of false positives due to population
stratification, but are not be able to detect SNP alleles associated
with smoking behavior that are common in non-Europeans but
rare among European-Americans. The smoking behavior charac-
teristics for the two studies are quite similar after taking into
account expected differences by gender (Table 1), and the
correlation of smoking behaviors are similar within NHS and
PLCO (see Table S1). The combined sample has the advantage of
increased power and generalizablity.
The diverse smoking behaviors we investigated represent the
spectrum of key events in an individual’s smoking history from
initiation (age at initiation, ever never smoking) thru establishment
of dependency (smoking duration, smoking intensity, and pack
Figure 3. 2log10 p-values for association with number of cigarettes smoked per day (CPD) for SNPs in the chr15q25.1 region. P-
values are based on the combined evidence for association from both PLCO and NHS. Filled symbols denote genotyped SNPs; open symbols denote
imputed SNPs. Black diamonds (squares) denote SNPs associated with continuous (binary) CPD in previous reports. Red circles denote SNPs
associated with lung cancer in previous reports.
doi:10.1371/journal.pone.0004653.g003
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with potential genetic influence at each stage. The finding that
selected genes are associated with multiple phenotypes may
represent both correlations among the phenotypes but also
pleiotropic effects of the genes, and is a strength of the integrative
approach [87]. Although we did not identify specific candidate
regions that achieved the genomewide threshold of statistical
significance, our study provides candidate genes for follow-up
evaluation. Future GWAS studies with additional smoking
behavioral measures, including nicotine dependence measures,
the planned sharing of data across large consortia with increased
sample size [88] and the functional analysis of individual SNPs
[89], will be required to achieve the necessary power and
specificity to understand SNP with low effects (OR,1.3), effects
in subgroups, explore effect modification by demographic
variables, and dissect pleiotropy.
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